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Background: As the HIV/AIDS pandemic has evolved over recent decades, Africa has been the most affected
region, even though a large proportion of HIV/AIDS deaths have not been documented at the individual
level. Systematic application of verbal autopsy (VA) methods in defined populations provides an opportunity
to assess the mortality burden of the pandemic from individual data.
Objective: To present standardised comparisons of HIV/AIDS-related mortality at sites across Africa and
Asia, including closely related causes of death such as pulmonary tuberculosis (PTB) and pneumonia.
Design: Deaths related to HIV/AIDS were extracted from individual demographic and VA data from 22
INDEPTH sites across Africa and Asia. VA data were standardised to WHO 2012 standard causes of death
assigned using the InterVA-4 model. Between-site comparisons of mortality rates were standardised using the
INDEPTH 2013 standard population.
Results: The dataset covered a total of 10,773 deaths attributed to HIV/AIDS, observed over 12,204,043
person-years. HIV/AIDS-related mortality fractions and mortality rates varied widely across Africa and Asia,
with highest burdens in eastern and southern Africa, and lowest burdens in Asia. There was evidence of
rapidly declining rates at the sites with the heaviest burdens. HIV/AIDS mortality was also strongly related to
PTB mortality. On a country basis, there were strong similarities between HIV/AIDS mortality rates at
INDEPTH sites and those derived from modelled estimates.
Conclusions: Measuring HIV/AIDS-related mortality continues to be a challenging issue, all the more so as
anti-retroviral treatment programmes alleviate mortality risks. The congruence between these results and other
estimates adds plausibility to both approaches. These data, covering some of the highest mortality observed
during the pandemic, will be an important baseline for understanding the future decline of HIV/AIDS.
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T
he human immunodeficiency virus (HIV) and the
consequent acquired immune deficiency syndrome
(AIDS) caused a globally devastating pandemic
starting in the late twentieth century. This pandemic
caused mortality of such a magnitude as to distort
population agesex distributions in the worst affected
areas (1). Now with the advent and roll-out of effective
treatment for case management, the situation is improv-
ing (2). However, because the pandemic most affected
those areas of the world where reliable health data are
scarcest, there remain large uncertainties about measur-
ing the impact of HIV/AIDS, with many assessments
relying on modelled estimates (3). Thus, in reality, many
millions of people attributed with HIV infection and/or
AIDS mortality over the course of the pandemic were
neither tested for the virus, nor had their deaths certified
by physicians.
In the absence of laboratory testing and physician
diagnosis, one way of determining the magnitude of HIV/
AIDS-related mortality is by using verbal autopsy (VA),
involving a structured interview with family or friends
after a death (4). The interview material is then used to
assign the cause of death. In many settings, particularly at
earlier stages, physiciansmade such assessments ofVAdata.
Recently, it has become more common to use compu-
terised models to attribute cause of death, which are faster,
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cheaper, and more consistent. Neither approach can be
regarded as absolutely correct. Following a VA interview,
assigning a death as due to HIV/AIDS is not entirely
straightforward, because HIV-infected people may die of
a variety of causes. As well as the wasting syndromes
typical of AIDS deaths, other causes of death, including
particularly pulmonary tuberculosis (PTB) and pneumo-
nia, occur at higher rates and in different age groups
among HIV-infected people.
In this paper, we present HIV/AIDS-specific mortality
rates as determined by computer-interpreted VA from 22
INDEPTH Network Health and Demographic Surveil-
lance Sites (HDSS) across Africa and Asia (5). These
findings are complemented with the corresponding rates
for PTB and pneumonia. Although these HDSSs are not
designed to form a representative network, each one
follows a geographically defined population longitudin-
ally, systematically recording all death events and under-
taking verbal autopsies on all deaths that occur. Our aim
is to present the HIV/AIDS mortality patterns at each
site, comparing these community-level findings with
other estimated information on HIV/AIDS in Africa
and Asia.
Methods
The overall INDEPTH dataset (6) from which these HIV/
AIDS-specific analyses are drawn is described in de-
tail elsewhere (7). The methods used are summarised in
Box 1. Briefly, it documents 111,910 deaths in 12,204,043
person-years of observation across 22 sites. The Karonga
site in Malawi did not contribute VAs for children.
Box 1. Summary of methodology based on the detailed
description in the introductory paper (7)
Agesextime standardisation
To avoid effects of differences and changes in age
sex structures of populations, mortality fractions
and rates have been adjusted using the INDEPTH
2013 population standard (8). A weighting factor
was calculated for each site, age group, sex, and
year category in relation to the standard for the
corresponding age group and sex, and incorpo-
rated into the overall dataset. This is referred to in
this paper as agesextime standardisation in the
contexts where it is used.
Cause of death assignment
The InterVA-4 (version 4.02) probabilistic model
was used for all the cause of death assignments in
the overall dataset (9). InterVA-4 is fully compliant
with the WHO 2012 Verbal Autopsy standard and
generates causes of death categorised by ICD-10
groups (10). The data reported here were collected
before the WHO 2012 VA standard was available,
but were transformed into the WHO 2012 and
InterVA-4 format to optimise cross-site standardi-
sation in cause of death attribution. For a small
proportion of deaths, VA interviews were not
successfully completed; a fewothers contained ina-
dequate information to arrive at a cause of death.
InterVA-4 assigns causes of death (maximum 3)
with associated likelihoods; thus cases for which
likely causes did not total to 100% were also assig-
Kilite-Awlaelo, Ethiopia:
CSMF 2.98%
0.13/1,000 py
Nairobi, Kenya:
CSMF 9.81%
1.00/1,000 py
Kilifi, Kenya:
CSMF 10.76%
0.65/1,000 py
Kisumu, Kenya:
CSMF 16.69%
3.09/1,000 py
Ouagadougou,
Burkina Faso:
CSMF 4.57%
0.27/1,000 py
Taabo,
Côte d'Ivoire:
CSMF 8.00%
0.77/1,000 py
Niakhar, Senegal:
CSMF 6.82%
0.55/1,000 py
Farafenni,
The Gambia:
CSMF 3.85%
0.41/1,000 py
Navrongo, Ghana:
CSMF 3.63%
0.35/1,000 py
Dodowa, Ghana:
CSMF 2.10%
0.16/1,000 py
Karonga, Malawi:
CSMF 14.26%
1.25/1,000 py
Agincourt, South Africa:
CSMF 18.85%
1.73/1,000 py
Africa Centre, South Africa:
CSMF 16.27%
2.49/1,000 py
Nouna, Burkina Faso:
CSMF 2.71%
0.26/1,000 py
Ballabgarh, India:
CSMF 0.27%
0.02/1,000 py
Bandarban, Bangladesh:
CSMF 3.83%
0.21/1,000 py
Matlab, Bangladesh:
CSMF 0.18%
0.01/1,000 py
AMK, Bangladesh:
CSMF 0.15%
0.01/1,000 py
Chakaria, Bangladesh:
CSMF 0.15%
0.01/1,000 py
FilaBavi, Vietnam:
CSMF 0.88%
0.03/1,000 py
Purworejo, Indonesia:
CSMF 0.38%
0.02/1,000 py
Vadu, India:
CSMF 1.89%
0.08/1,000 py
Fig. 1. Map showing participating sites, with agesextime adjusted cause-specific mortality fractions and adjusted mortality
rates for HIV/AIDS.
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ned a residual indeterminate component. This
served as a means of encapsulating uncertainty in
cause of death at the individual level within the
overall dataset, as well as accounting for 100% of
every death.
Overall dataset
The overall public-domain dataset (6) thus con-
tains between one and four records for each death,
with the sum of likelihoods for each individual
being unity. Each record includes a specific cause
of death, its likelihood and its agesextime
weighting.
The InterVA-4 ‘high’ HIV/AIDS setting was used for
sites in Kenya, Malawi, and South Africa. All other sites
used the ‘low’ setting; the ‘very low’ setting was not used.
The InterVA-4 guideline is that the ‘high’ setting is appro-
priate for an expected HIV/AIDS cause-specific mortality
fraction (CSMF) higher than about 1%, though it does not
result in any great dichotomisation of outputs; the clinical
equivalent is a physician’s knowledge that his/her current
case comes from a setting where HIV/AIDS is more or less
likely, irrespective of that current case’s particular symptoms.
The validity of the InterVA-4 model in assigning HIV/
AIDS as a cause of death in relation to HIV sero-status
has been extensively explored in conjunction with the
ALPHANetwork (11), and found to be over 90% specific.
Sensitivity is more difficult to assess, since not all people
infected with HIV evidently die of AIDS. The same vali-
dation exercise pointed to large numbers of cases of PTBand
pneumonia as causes of death among the HIV-positive.
Deaths assigned to HIV/AIDS, and the closely related
causes of PTB and pneumonia, were extracted from the
overall data set together with data on person-time ex-
posed by site, year, age, and sex. As each HDSS covers
a total population, rather than a sample, uncertainty
intervals are not shown.
For the sake of comparisonwith other estimates ofHIV/
AIDS-related mortality, unadjusted data were extracted
for all sites for the period 20082012 (excluding data from
the Farafenni, The Gambia; Purworejo, Indonesia; and
FilaBavi, Vietnam sites which did not report for that
period). These data were grouped into three age bands
(014, 1549, and 50 ) and aggregated by country,
to facilitate comparison with contemporaneous national
point estimates for 2010.
In this context, all of these data are secondary datasets
derived from primary data collected separately by each
participating site. In all cases, the primary data collection
was covered by site-level ethical approvals relating to
on-going health and demographic surveillance in those
specific locations. No individual identity or household
location data were included in the secondary data and no
specific ethical approvals were required for these pooled
analyses.
Results
In the overall dataset, there were 10,455.4 deaths
attributed to HIV/AIDS (including fractions of 11,972
individual deaths), with a further 10,363.4 deaths attrib-
uted to acute respiratory infections (including pneumo-
nia), and 12,874.8 attributed to PTB.
The agesextime standardised CSMFs for HIV/AIDS
at each site are shown, together with the population-based
HIV/AIDS-specific mortality rate per 1,000 person-years,
in Fig. 1. In West African sites, HIV/AIDS CSMF ranged
from 2.10 to 8.00%, with HIV/AIDS-specific adjusted
mortality rates ranging from 0.16 to 0.77 per 1,000 person-
years. In eastern and southern Africa, except Ethiopia,
CSMFswere 9.8118.85%, with rates from 0.65 to 3.09 per
1,000 person-years. In Asia, CSMFs were 0.153.83%,
with rates from 0.01 to 0.21 per 1,000 person-years.
Figure 2 shows HIV/AIDS mortality epidemic cur-
ves for the five sites where overall HIV/AIDS mortality
was at least 1 per 1,000 person-years. Apart from the
Agincourt, South Africa, site, for which a more or less
complete epidemic curve can be seen, the other sites
recorded mortality during a period of mainly declining
HIV/AIDS mortality.
Table 1 gives HIV/AIDS-specific mortality rates by age
group and site. During infancy, the highest HIV/AIDS-
specific mortality rate was reported from the Africa
Centre, South Africa (7.00 per 1,000 person-years),
contrasting with a zero rate from several Asian sites.
For the 14 age group, the Kisumu, Kenya, site recorded
the highest rate (5.40 per 1,000 person-years). In the 514
year age group, Asian sites recorded rates from 0 to 0.07
per 1,000 person-years, compared with African sites from
0.02 to 0.40 per 1,000 person-years. In adulthood, the
ranges across Asian sites for 1549 years, 5064 years,
and 65 years were 00.23, 0.020.66, and 00.09,
respectively. Similarly for African sites, ranges were
0.083.65, 0.374.56, and 02.26, respectively.
Figure 3 shows the relationships between agesextime
standardised HIV/AIDS mortality rates and PTB mor-
tality rates for all 22 sites. Seven of the eight sites in Asia
had an HIV/AIDS rate below 0.1 per 1,000 person-years,
but PTB rates ranged from 0.11 to 0.75 per 1,000 person-
years. Conversely, six of the seven sites in eastern and
southern Africa had HIV/AIDS rates above 0.5 per 1,000
person-years, with PTB rates ranging from 0.52 to 4.96
per 1,000 person-years. The highest agesextime stan-
dardised HIV/AIDS mortality rate ratio was between
Kisumu, Kenya, and AMK, Bangladesh, at 343:1.
Figure 4 shows HIV/AIDS mortality rates for 15 sites
which had an overall HIV/AIDS-specific mortality rate
over 0.1 per 1,000 person-years, by age group, also
showing corresponding data for PTB and pneumonia.
Logarithmic scales have been used to visualise both high
and low levels of mortality while using the same scale for
each site.
INDEPTH Network
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Table 2 shows the INDEPTH results in comparison
with national estimates from the UNAIDS Spectrum
model (12) and Global Burden of Disease 2010 (13).
Longitudinal INDEPTH datawere aggregated over 2008
2012 (for the 19 sites reporting for that period) for the
purposes of comparison with the Spectrum and Global
Burden of Disease 2010 (GBD 2010) estimates, together
with corresponding estimates for PTB.
Discussion
Against the background of extensive modelling ap-
proaches that have been applied to HIV/AIDS mortality,
this dataset presents results from individually documen-
ted deaths at a range of sites across Africa and Asia. The
expected huge differences in HIV/AIDS mortality rates
between Africa and Asia were evident from these results,
and, to a lesser extent, the substantial differences that
occurred within the African continent. The good news is
that HIV/AIDS deaths declined in recent years in all the
sites with high mortality rates (Fig. 2), as the effects of
prevention and treatment programmes took effect. The
interpretation of findings at individual sites depends on
local characteristics (1435). Two sites, Ouagadougou in
Burkina Faso and Nairobi in Kenya, followed urban
populations. Bandarban in Bangladesh is located in a
militarised frontier zone close to the Myanmar border,
which may be associated with higher rates of HIV/AIDS
mortality compared with other sites in Bangladesh.
The validity of VA cause of death assignment for HIV/
AIDS is not straightforward. In these results, the similar
and marked changes over time in the high mortality sites
(Fig. 2) added veracity to the InterVA-4 outputs, since the
model had no information about the progress of the
epidemic over time. Similarly, the extremely low levels of
HIV/AIDS-related death assigned as a cause in countries
such as Bangladesh and India confirmed the specificity of
the methods used. A previous assessment of InterVA-4
validity versus HIV sero-status showed high specificity,
but sensitivity was unmeasurable since not all HIV-
positive people go on to die from HIV/AIDS (11).
However, the same study also showed high mortality
rate ratios for PTB and pneumonia between HIV positive
and negative cases. ICD-10 classification (36) suggests
that almost all HIV-related deaths should be classified
under the B20-B24 rubrics, but this is easier said than
done in practice, either when using VA or when certifying
a death, if there is no evidence of HIV status. In view of
the apparently complex relationships between HIV/AIDS
deaths and PTB deaths in different settings, as evidenced
in Fig. 3, it is not simply a matter of adding together
HIV/AIDS and PTB deaths across all settings. However,
the total of what InterVA-4 assigns as HIV/AIDS and
PTB deaths may provide a better approximation of the
overall burden of HIV/AIDS-related mortality for at
least the 1549 year age group in high HIV settings.
The question of HIV/AIDS-related mortality associated
with pregnancy has also been a matter of debate (37).
Another paper in this series analyses pregnancy-related
mortality in detail, including the attribution of HIV/
AIDS-related deaths between indirect maternal and
incidental categories (38).
The WHO 2012 VA standard (39) includes an indi-
cator relating to previous diagnosis of HIV, although
the validation study suggested that this was seriously
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Fig. 2. Epidemic curves for HIV/AIDS mortality rates for
the five sites where overall HIV/AIDS mortality exceeded 1
per 1,000 person-years.
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Table 1. HIV/AIDS-specific deaths and mortality rates per 1,000 person-years, by age group and site, from 111,910 deaths in
12,204,043 person-years of observation across 22 sites
Age group at death
Country: Site Infant 14 years 514 years 1549 years 5064 years 65 years
Bangladesh: Matlab
Adjusted deaths 1.71 7.23 2.18 4.16 3.17 0.00
Rate/1,000 py 0.04 0.04 0.01 0.00 0.02 0.00
Bangladesh: Bandarban
Adjusted deaths 1.19 0.00 1.00 7.02 3.89 0.00
Rate/1,000 py 0.96 0.00 0.07 0.23 0.66 0.00
Bangladesh: Chakaria
Adjusted deaths 0.36 0.00 0.00 0.00 1.71 0.00
Rate/1,000 py 0.06 0.00 0.00 0.00 0.11 0.00
Bangladesh: AMK
Adjusted deaths 0.00 1.44 0.87 0.74 1.00 0.00
Rate/1,000 py 0.00 0.03 0.01 0.00 0.02 0.00
Burkina Faso: Nouna
Adjusted deaths 7.92 51.12 8.89 88.29 20.34 3.11
Rate/1,000 py 0.26 0.49 0.05 0.32 0.43 0.11
Burkina Faso: Ouagadougou
Adjusted deaths 11.55 16.15 4.63 19.85 7.57 0.00
Rate/1,000 py 1.66 0.58 0.09 0.17 0.66 0.00
Coˆte d’Ivoire: Taabo
Adjusted deaths 10.20 20.09 8.24 28.95 7.23 5.06
Rate/1,000 py 2.57 1.55 0.27 0.60 1.04 1.59
Ethiopia: Kilite Awlaelo
Adjusted deaths 1.91 2.91 0.87 4.85 4.13 1.89
Rate/1,000 py 0.60 0.22 0.02 0.08 0.37 0.27
The Gambia: Farafenni
Adjusted deaths 13.14 44.29 11.86 40.20 20.01 3.86
Rate/1,000 py 1.15 1.03 0.13 0.29 0.89 0.34
Ghana: Navrongo
Adjusted deaths 31.16 92.71 24.70 195.22 52.08 10.61
Rate/1,000 py 1.03 0.80 0.08 0.37 0.41 0.15
Ghana: Dodowa
Adjusted deaths 5.09 10.80 10.01 41.98 13.51 2.86
Rate/1,000 py 0.36 0.19 0.07 0.16 0.37 0.11
India: Ballabgarh
Adjusted deaths 0.00 1.44 0.61 2.66 2.21 0.00
Rate/1,000 py 0.00 0.05 0.01 0.01 0.07 0.00
India: Vadu
Adjusted deaths 8.42 0.00 0.00 2.25 1.23 0.00
Rate/1,000 py 1.96 0.00 0.00 0.02 0.08 0.00
Indonesia: Purworejo
Adjusted deaths 0.00 0.00 1.34 0.00 3.35 1.98
Rate/1,000 py 0.00 0.00 0.03 0.00 0.12 0.09
Kenya: Kilifi
Adjusted deaths 69.17 70.79 60.88 276.26 99.83 50.99
Rate/1,000 py 1.80 0.48 0.20 0.65 1.52 1.54
Kenya: Kisumu
Adjusted deaths 297.87 780.55 128.47 1708.84 406.33 132.85
Rate/1,000 py 7.47 5.40 0.40 3.65 4.56 1.98
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under-reported in VA interviews (11). The WHO 2012
standard, and therefore InterVA-4, does not yet include
any details of anti-retroviral therapy (ART), although that
will become a more pressing issue as experience of
mortality patterns among HIV positive individuals with
long exposure toARTdevelops. It is as yet a relativelyopen
question as towhat the major causes of death amongHIV-
positive people might be after possible decades of ART.
There are other major pieces of work describing HIV/
AIDS mortality patterns across Africa and Asia, but
Table 1 (Continued )
Age group at death
Country: Site Infant 14 years 514 years 1549 years 5064 years 65 years
Kenya: Nairobi
Adjusted deaths 66.99 81.34 18.42 356.93 44.46 4.34
Rate/1,000 py 4.67 1.30 0.17 0.93 1.79 0.77
Malawi: Karonga
Adjusted deaths
n/a n/a n/a
226.10 50.15 16.82
Rate/1,000 py 1.92 3.39 1.48
Senegal: Niakhar
Adjusted deaths 2.68 16.06 11.39 62.15 21.95 7.05
Rate/1,000 py 0.30 0.50 0.19 0.64 1.37 0.66
South Africa: Agincourt
Adjusted deaths 140.09 302.84 67.11 1434.89 309.61 142.86
Rate/1,000 py 3.81 2.03 0.18 1.98 3.35 2.26
South Africa: Africa Centre
Adjusted deaths 157.25 232.14 55.38 1227.58 210.72 74.44
Rate/1,000 py 7.00 2.54 0.24 3.28 3.84 1.90
Vietnam: FilaBavi
Adjusted deaths 0.32 0.00 0.00 3.02 2.80 0.00
Rate/1,000 py 0.15 0.00 0.00 0.04 0.17 0.00
Burkina FasoBurkina Faso
Côte d'Ivoire
Ghana
Ghana
The Gambia
Senegal
Ethiopia
Kenya
Kenya
Kenya
Malawi
South Africa
South Africa
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Fig. 3. Relationship between HIV/AIDS and pulmonary TB agesextime standardised mortality rates for 22 INDEPTH
Network sites in Africa and Asia.
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these largely relied on modelling estimates from whatever
specific sources of data were available, and therefore
carried large degrees of uncertainty given the sparse
nature of the data from many settings. The two major
sources of contemporaneous estimates for HIV/AIDS
mortality come from the UNAIDS Spectrum model (12)
and the GBD 2010 model (13). Although our purpose
here is not to compare these two models with each other,
it is worth noting that there are some major differences.
For example, among the countries represented here, the
estimates for Ethiopia vary three-fold.
Table 2 shows estimates of HIV/AIDS-related and
PTB mortality rates for 12 countries according to
Spectrum, GBD 2010, and InterVA-4, which in many
cases were very similar, though with differences in places.
It must be remembered that these comparisons were
compromised by taking INDEPTH sites that are not
designed to be nationally representative and putting their
findings alongside modelled estimates that are intended
to reflect national situations. In South Africa, it appeared
that InterVA-4 assigned a substantial amount of HIV/
AIDS mortality as PTB, which is perhaps unsurprising in
that high-prevalence setting. InterVA-4 arrived at a
substantially higher HIV/AIDS mortality estimate than
Spectrum for Senegal, and vice-versa for India. There were
also many similarities in PTB mortality rates, though
differences were evident in Ghana, Kenya, and Senegal.
Similarly there were relatively few appreciable differ-
ences between GBD 2010 and InterVA-4 estimates. The
differences may reflect local disparities in rates between
sites and national populations, given that the relationships
between symptoms and causes would not be expected
to vary substantially between countries. It also has to be
remembered that, although all these VAs have been pro-
cessed in a standardised way using the WHO 2012 pro-
tocol, they were collected in the field in slightly different
ways before 2012, and some observed differences may also
reflect that. Overall, however, there was appreciable con-
gruence in mortality rates between these various sources.
Conclusions
Measuring HIV/AIDS mortality continues to be a highly
challenging area, particularly in Africa, where rates are
high and data are often unavailable. This is the largest
single systematic study that has applied common meth-
odologies to HIV/AIDS mortality at the individual level
across Africa and Asia, and it largely confirms the
corresponding findings coming from modelled estimates.
This mutually adds plausibility to both existing estimates
and to these population-based findings. The challenges
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Fig. 4. Mortality rates for HIV/AIDS, pulmonary TB, and pneumonia, by site and age group at 15 INDEPTH Network sites
for which the overall rate of HIV/AIDS mortality exceeded 0.1/1,000 person-years.
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involved in measuring HIV/AIDS mortality will grow as
ART coverage and individual duration on treatment in-
crease; in many ways, these results represent an important
baseline for future studies of the treated pandemic.
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